Abstract
Despite an increase in the variety of anti-retroviral agents in the market, there remains a need for novel agents to treat HIV 1 infected individuals, in order to overcome existing problems with adherence, toxicities, drug interactions and viral resistance. In this article, we will describe Pro 140, one of the recently developed class of anti-retroviral agent, the CCR5 co-receptor inhibitor. We will also describe several preclinical and clinical studies that have evaluated the efficacy, tolerability and toxicity profiles of Pro 140. We will also look at how its mechanism of action and mode of delivery may change the way patients take highly active anti-retroviral therapy. There are some promising patents discussed in this short review for the use of PRO 140 as CCR5 co-receptor inhibitor.
Keywords: Pro 140, CCR5 co-receptor inhibitor, entry inhibitors
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Drug Safety
Current Drug Targets
Current Medicinal Chemistry
Current Pharmaceutical Biotechnology
Central Nervous System Agents in Medicinal Chemistry
Infectious Disorders - Drug Targets
Letters in Drug Design & Discovery
Current HIV Research
Related Books
Marine Biopharmaceuticals: Scope and Prospects
COVID 19 – Monitoring with IoT Devices
Frontiers in Clinical Drug Research: Anti-Infectives
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Recent Advances in the Application of Marine Natural Products as Antimicrobial Agents
Recent Trends and The Future of Antimicrobial Agents - Part 2
COVID-19: Origin, Impact and Management (Part 2)
Frontiers in Anti-Infective Drug Discovery
COVID-19: Origin, Impact and Management, Part 1
Toll-Like Receptors in Vector-borne Diseases
23